新焦點(00360.HK)所涉訴訟被索償近4,000萬元人幣
新焦點(00360.HK)公佈,全資附屬公司內蒙古創贏,在早前收到赤峯市利豐提出的訴訟後,近日收到另一份傳票及赤峯市利豐提交的變更訴訟請求申請書,被要求於8月30日到法院應訊。
赤峯市利豐聲稱其中一名被告利豐鼎盛,利用其作爲赤峯市利豐前控股股東的身份,向內蒙古創贏轉讓十二間營運公司的股權,且未提供任何對價,請求法院判決內蒙古創贏及利豐鼎盛賠償合計3,999.88萬元人民幣,及承擔訴訟費用。
公司正就申請書的影響尋求法律意見,並評估上述訴訟請求變更後可能造成的或然負債。內蒙古創贏將繼續積極應對上述訴訟。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.